Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000930413-25-002258
Filing Date
2025-07-28
Accepted
2025-07-28 11:38:34
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12847
2 c113519_ex1.htm EX-1 3615
  Complete submission text file 0000930413-25-002258.txt   18215
Mailing Address 2 OVERHILL ROAD SCARSDALE NY 10583
Business Address 2 OVERHILL ROAD SCARSDALE NY 10583 212.974.3070
Iroquois Capital Management, LLC (Filed by) CIK: 0001481867 (see all company filings)

EIN.: 010786483 | State of Incorp.: DE
Type: SCHEDULE 13G

Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Subject) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92289 | Film No.: 251154318
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)